Cargando…

Advancing to the era of cancer immunotherapy

Cancer greatly affects the quality of life of humans worldwide and the number of patients suffering from it is continuously increasing. Over the last century, numerous treatments have been developed to improve the survival of cancer patients but substantial progress still needs to be made before can...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yun, Wang, Min, Wu, Hao‐Xiang, Xu, Rui‐Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441060/
https://www.ncbi.nlm.nih.gov/pubmed/34165252
http://dx.doi.org/10.1002/cac2.12178
_version_ 1783752799178194944
author Wang, Yun
Wang, Min
Wu, Hao‐Xiang
Xu, Rui‐Hua
author_facet Wang, Yun
Wang, Min
Wu, Hao‐Xiang
Xu, Rui‐Hua
author_sort Wang, Yun
collection PubMed
description Cancer greatly affects the quality of life of humans worldwide and the number of patients suffering from it is continuously increasing. Over the last century, numerous treatments have been developed to improve the survival of cancer patients but substantial progress still needs to be made before cancer can be truly cured. In recent years, antitumor immunity has become the most debated topic in cancer research and the booming development of immunotherapy has led to a new epoch in cancer therapy. In this review, we describe the relationships between tumors and the immune system, and the rise of immunotherapy. Then, we summarize the characteristics of tumor‐associated immunity and immunotherapeutic strategies with various molecular mechanisms by showing the typical immune molecules whose antibodies are broadly used in the clinic and those that are still under investigation. We also discuss important elements from individual cells to the whole human body, including cellular mutations and modulation, metabolic reprogramming, the microbiome, and the immune contexture. In addition, we also present new observations and technical advancements of both diagnostic and therapeutic methods aimed at cancer immunotherapy. Lastly, we discuss the controversies and challenges that negatively impact patient outcomes.
format Online
Article
Text
id pubmed-8441060
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84410602021-09-15 Advancing to the era of cancer immunotherapy Wang, Yun Wang, Min Wu, Hao‐Xiang Xu, Rui‐Hua Cancer Commun (Lond) Reviews Cancer greatly affects the quality of life of humans worldwide and the number of patients suffering from it is continuously increasing. Over the last century, numerous treatments have been developed to improve the survival of cancer patients but substantial progress still needs to be made before cancer can be truly cured. In recent years, antitumor immunity has become the most debated topic in cancer research and the booming development of immunotherapy has led to a new epoch in cancer therapy. In this review, we describe the relationships between tumors and the immune system, and the rise of immunotherapy. Then, we summarize the characteristics of tumor‐associated immunity and immunotherapeutic strategies with various molecular mechanisms by showing the typical immune molecules whose antibodies are broadly used in the clinic and those that are still under investigation. We also discuss important elements from individual cells to the whole human body, including cellular mutations and modulation, metabolic reprogramming, the microbiome, and the immune contexture. In addition, we also present new observations and technical advancements of both diagnostic and therapeutic methods aimed at cancer immunotherapy. Lastly, we discuss the controversies and challenges that negatively impact patient outcomes. John Wiley and Sons Inc. 2021-06-24 /pmc/articles/PMC8441060/ /pubmed/34165252 http://dx.doi.org/10.1002/cac2.12178 Text en © 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Wang, Yun
Wang, Min
Wu, Hao‐Xiang
Xu, Rui‐Hua
Advancing to the era of cancer immunotherapy
title Advancing to the era of cancer immunotherapy
title_full Advancing to the era of cancer immunotherapy
title_fullStr Advancing to the era of cancer immunotherapy
title_full_unstemmed Advancing to the era of cancer immunotherapy
title_short Advancing to the era of cancer immunotherapy
title_sort advancing to the era of cancer immunotherapy
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441060/
https://www.ncbi.nlm.nih.gov/pubmed/34165252
http://dx.doi.org/10.1002/cac2.12178
work_keys_str_mv AT wangyun advancingtotheeraofcancerimmunotherapy
AT wangmin advancingtotheeraofcancerimmunotherapy
AT wuhaoxiang advancingtotheeraofcancerimmunotherapy
AT xuruihua advancingtotheeraofcancerimmunotherapy